ArticleFrontiers in surgery2020

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.

M R Chambers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.